Phase I trial of multidrug resistance-associated protein 3-derived peptide in patients with hepatocellular carcinoma

フォーマット:

論文

責任表示:

Mizukoshi, Eishiro ; Nakagawa, Hidetoshi ; Kitahara, Masaaki ; Yamashita, Tatsuya ; Arai, Kuniaki ; Sunagozaka, Hajime ; Iida, Noriho ; Fushimi, Kazumi ; Kaneko, Shuichi

言語:

英語

出版情報:

Elsevier, 2015-12-01

著者名:

Mizukoshi, Eishiro

Nakagawa, Hidetoshi

Kitahara, Masaaki

Yamashita, Tatsuya

Arai, Kuniaki

Sunagozaka, Hajime

Iida, Noriho

Fushimi, Kazumi

Kaneko, Shuichi

続きを見る

掲載情報:

Cancer Letters

ISSN:

0304-3835      

巻:

369

通号:

1

開始ページ:

242

終了ページ:

249

バージョン:

author

概要:

Multidrug resistance-associated protein 3 (MRP3) is a carrier-type transport protein belonging to the ABC transporters. In this study, we investigated the safety and immunogenicity of a MRP3-derived peptide (MRP3765) as a vaccine and characterized the MRP3-specific T cell responses induced. Twelve hepatocellular carcinoma (HCC) patients treated with hepatic arterial infusion chemotherapy (HAIC) were enrolled. The MRP3-derived peptide was emulsified in incomplete … Freund's adjuvant and administered via subcutaneous immunization three times weekly. No serious adverse drug reactions to the peptide vaccine were observed, and the vaccination was well tolerated. The vaccination induced MRP3-specific immunity in 72.7% of the patients. In a phenotypic analysis, the largest post-vaccinated increase in MRP3-specific T cells was due to an increase in cells with the effector memory phenotype. Among the 12 patients, one patient showed a partial response, nine showed a stable disease, and two showed a progressive disease. The median overall survival time was 14.0 months. In conclusion, the safety, effects of immune boosting, and possible prolongation of overall survival by the MRP3-derived peptide demonstrate the potential of the peptide to provide clinical benefit in HCC patients. © 2015. 続きを見る

URL:

http://hdl.handle.net/2297/43914